Product
Trifluridine + Tipiracil
Aliases
LONSURF
5 clinical trials
5 indications
Indication
Colorectal CancerIndication
Gastric AdenocarcinomaIndication
Second LineIndication
ChemotherapyIndication
Locally Advanced Rectal CancerClinical trial
Prospective, Randomized, Open, Multicenter Phase II Trial to Investigate the Efficacy of Trifluridine/Tipiracil Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer: FIRE-8; AIO-KRK/YMO-0519Status: Recruiting, Estimated PCD: 2029-12-01
Clinical trial
A Randomized, Phase II Study Comparing the Sequences of Regorafenib and Trifluridine/Tipiracil, After Failure of Standard Therapies in Patients With Metastatic Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2024-11-23
Clinical trial
Multicentric Randomized Phase I/II Study to Evaluate Efficacy of Trifluridine/Tipiracil Plus XB2001 (Anti-IL-1α True Human Antibody) Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, FluoropyrimidineStatus: Recruiting, Estimated PCD: 2026-10-13
Clinical trial
A Phase Ib/II Study of Ramucirumab (Cyramza®), Nal-IRI (ONIVYDE®) and Trifluridine/Tipiracil (Lonsurf®) in Second Line Metastatic Gastric Cancer (COOL Study).Status: Not yet recruiting, Estimated PCD: 2025-08-31
Clinical trial
Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II TARC TrialStatus: Terminated, Estimated PCD: 2022-09-02